Recent discovery and development of inhibitors targeting coronaviruses
T Pillaiyar, S Meenakshisundaram, M Manickam - Drug discovery today, 2020 - Elsevier
Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded
RNA genome. Currently, six human CoVs have been reported including human coronavirus …
RNA genome. Currently, six human CoVs have been reported including human coronavirus …
Flavonoids: promising natural compounds against viral infections
Flavonoids are widely distributed as secondary metabolites produced by plants and play
important roles in plant physiology, having a variety of potential biological benefits such as …
important roles in plant physiology, having a variety of potential biological benefits such as …
Inhibitors of SARS-CoV-2 entry: current and future opportunities
Recently, a novel coronavirus initially designated 2019-nCoV but now termed SARS-CoV-2
has emerged and raised global concerns due to its virulence. SARS-CoV-2 is the etiological …
has emerged and raised global concerns due to its virulence. SARS-CoV-2 is the etiological …
Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture
AH De Wilde, D Jochmans, CC Posthuma… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Coronaviruses can cause respiratory and enteric disease in a wide variety of human and
animal hosts. The 2003 outbreak of severe acute respiratory syndrome (SARS) first …
animal hosts. The 2003 outbreak of severe acute respiratory syndrome (SARS) first …
Therapeutic potential of coumarins as antiviral agents
Coumarins have received a considerable attention in the last three decades as a lead
structures for the discovery of orally bioavailable non-peptidic antiviral agents. A lot of …
structures for the discovery of orally bioavailable non-peptidic antiviral agents. A lot of …
Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention
Chikungunya (CHIK) is a disabling and debilitating zoonotic disease of humans caused by
the Chikungunya virus (CHIKV), which is transmitted by CHIKV-infected Aedes spp …
the Chikungunya virus (CHIKV), which is transmitted by CHIKV-infected Aedes spp …
Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies
J Dyall, R Gross, J Kindrachuk, RF Johnson… - Drugs, 2017 - Springer
No specific antivirals are currently available for two emerging infectious diseases, Middle
East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A …
East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A …
Repurposing sigma-1 receptor ligands for COVID-19 therapy?
JM Vela - Frontiers in Pharmacology, 2020 - frontiersin.org
Outbreaks of emerging infections, such as COVID-19 pandemic especially, confront health
professionals with the unique challenge of treating patients. With no time to discover new …
professionals with the unique challenge of treating patients. With no time to discover new …
Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses
FS Varghese, P Kaukinen, S Gläsker, M Bespalov… - Antiviral research, 2016 - Elsevier
Chikungunya virus (CHIKV) is an arthritogenic arbovirus of the Alphavirus genus, which has
infected millions of people after its re-emergence in the last decade. In this study, a BHK cell …
infected millions of people after its re-emergence in the last decade. In this study, a BHK cell …
A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery
T Pillaiyar, S Meenakshisundaram, M Manickam… - European journal of …, 2020 - Elsevier
Drug repurposing is a strategy consisting of finding new indications for already known
marketed drugs used in various clinical settings or highly characterized compounds despite …
marketed drugs used in various clinical settings or highly characterized compounds despite …